Sykała, M.; Szumowski, P.; Mojsak, M.; Abdelrazek, S.; Żukowski, Ł.; Lipińska, D.; Juchnicka, I.; Kozłowska, G.; Szelachowska, M.; Krętowski, A.;
et al. Assessment of Clinical Utility of Assaying FGF-23, Klotho Protein, Osteocalcin, NTX, and Sclerostin in Patients with Primary Hyperparathyroidism. J. Clin. Med. 2021, 10, 3089.
https://doi.org/10.3390/jcm10143089
AMA Style
Sykała M, Szumowski P, Mojsak M, Abdelrazek S, Żukowski Ł, Lipińska D, Juchnicka I, Kozłowska G, Szelachowska M, Krętowski A,
et al. Assessment of Clinical Utility of Assaying FGF-23, Klotho Protein, Osteocalcin, NTX, and Sclerostin in Patients with Primary Hyperparathyroidism. Journal of Clinical Medicine. 2021; 10(14):3089.
https://doi.org/10.3390/jcm10143089
Chicago/Turabian Style
Sykała, Monika, Piotr Szumowski, Małgorzata Mojsak, Saeid Abdelrazek, Łukasz Żukowski, Danuta Lipińska, Ilona Juchnicka, Gabryela Kozłowska, Małgorzata Szelachowska, Adam Krętowski,
and et al. 2021. "Assessment of Clinical Utility of Assaying FGF-23, Klotho Protein, Osteocalcin, NTX, and Sclerostin in Patients with Primary Hyperparathyroidism" Journal of Clinical Medicine 10, no. 14: 3089.
https://doi.org/10.3390/jcm10143089
APA Style
Sykała, M., Szumowski, P., Mojsak, M., Abdelrazek, S., Żukowski, Ł., Lipińska, D., Juchnicka, I., Kozłowska, G., Szelachowska, M., Krętowski, A., & Myśliwiec, J.
(2021). Assessment of Clinical Utility of Assaying FGF-23, Klotho Protein, Osteocalcin, NTX, and Sclerostin in Patients with Primary Hyperparathyroidism. Journal of Clinical Medicine, 10(14), 3089.
https://doi.org/10.3390/jcm10143089
